Stefan Knapp

The paper introduces PFI-7, a chemical probe that inhibits GID4 Pro/N-degron interactions, revealing non-degradative roles of the CTLH complex in human cells.

The paper identifies epoxykynin as a potent sEH inhibitor that modulates the kynurenine pathway, offering new opportunities to address cancer-induced immune tolerance.

This study develops selective MST3/4 kinase inhibitors and demonstrates their distinct cellular effects compared to MST1/2 inhibition.

This study identifies compound 6 as a potent Slack potassium channel activator effective in treating histamine-independent and chronic itch without motor side effects.

This study develops potent dual BET/HDAC inhibitors through pharmacophore merging and structure-guided optimization, showing improved potency and efficacy in cancer cell models.

This paper provides a detailed protocol for producing LIR peptides and using ITC to study their interactions with LC3/GABARAP proteins, including troubleshooting guidance.

The paper designs and synthesizes a macrocyclic inhibitor, JA310, that selectively targets MST3 with high potency and kinome-wide selectivity.

This study presents cryo-EM structures of LRRK2 bound to type-I and type-II inhibitors, revealing conformational changes and providing a basis for inhibitor design.

This paper develops cell-based assays to monitor PROTAC degradation kinetics and ternary complex formation, revealing that ternary complex stability is critical for PROTAC efficiency.

The paper shows that TAp63 uses a slow third phosphorylation step to set a threshold for apoptosis induction in response to DNA damage.

The paper describes efforts to crystallize the Parkinson’s disease protein LRRK2 under microgravity conditions to improve diffraction quality for structure determination.